Works matching IS 19450877 AND DT 2018 AND VI 11 AND IP 551

Results: 5
    1
    2
    3
    4

    Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

    Published in:
    Science Signaling, 2018, v. 11, n. 551, p. 1, doi. 10.1126/scisignal.aat9773
    By:
    • Cocco, Emiliano;
    • Javier Carmona, F.;
    • Razavi, Pedram;
    • Won, Helen H.;
    • Cai, Yanyan;
    • Rossi, Valentina;
    • Chan, Carmen;
    • Cownie, James;
    • Soong, Joanne;
    • Toska, Eneda;
    • Shifman, Sophie G.;
    • Sarotto, Ivana;
    • Savas, Peter;
    • Wick, Michael J.;
    • Papadopoulos, Kyriakos P.;
    • Moriarty, Alyssa;
    • Cutler, Richard E.;
    • Avogadri-Connors, Francesca;
    • Lalani, Alshad S.;
    • Bryce, Richard P.
    Publication type:
    Article
    5